Solna, December 28, 2022 – Vivesto AB, an oncology-focused specialty pharma company, announced today that the company's new permanent CEO Erik Kinnman will take up his position on January 23, 2023.
Erik Kinnman has 27 years of experience from senior positions in Life Science, including AstraZeneca and Sobi, and has worked as a financial analyst at Danske Bank. He has been CEO for five years for Abliva, CEO of Sprint Bioscience for two years, and holds board member positions for Stayble and ISR. Erik has a background as a doctor specializing in neurology and pain management and is an associate professor at Karolinska Institutet.
"Erik will take up the position of CEO at an exciting and crucial time in the company's development. With the broad experience from leading positions in listed Life Science companies, the Board looks with confidence at the future of the company under his leadership," said Peter Zonabend, Chairman of the Board of Vivesto.
"I see significant opportunities in the portfolio and technology platform developed by Vivesto, while there are great opportunities to further develop the business and add new treatment opportunities in cancer. I will work to ensure that we build value for our shareholders while developing new treatment options for cancer where there are remaining medical needs,” said Erik Kinnman, incoming CEO of Vivesto.
"At the same time, we would like to thank Christer Nordstedt for his important contribution in his role as acting CEO of Vivesto," said Peter Zonabend. He has for a short time demonstrated his broad competence and long experience from the industry, not least when it comes to the company's continued development in research and development."
Christer Nordstedt will remain as senior advisor to Vivesto on a consulting basis in research and development.
For further information:
Peter Zonabend, Chairman of the Board of Vivesto
Phone: +46 18-50 54 40
E-mail: IR@vivesto.com
About Vivesto AB
Vivesto is a specialty pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of clinical-stage projects targeting advanced cancer. Apealea® (paclitaxel micellar) is made available to patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in long-developed ovarian cancer, and Docetaxel micellar being developed for metastatic prostate cancer. Vivesto's proprietary and patented technology platform is developed to improve the water solubility, efficacy and safety of pharmaceuticals. The company's shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.